New trial
Phase 1 trial of PHOX2B PC-CAR T, a PHOX2B-directed CAR-T therapy
- Trial ID
- NCT07007117 on ClinicalTrials.gov
- Cancer type
- Neuroendocrine Tumor
- Stage of research
- First-in-human
- Published in
- New in Oncology - July 3, 2025
This first-in-human dose escalation trial uses a standard 3+3 design to determine the maximum tolerated dose in patients with relapsed or refractory high‐risk neuroblastoma. The study, led by Stephan Grupp MD PhD in Philadelphia, aims to assess safety and preliminary tumor response.
More in neuroendocrine and adrenal tumors
-
Trial result · Oct 15, 2026 · NCT00107289
Single ¹³¹I-MIBG (NET-targeted radiopharmaceutical) + single autologous stem cell rescue shows feasible engraftment but low response in resistant neuroblastoma -
Trial result · Aug 27, 2026 · NCT03972488
¹⁷⁷Lu-DOTATATE (SSTR-targeted PRRT) extends PFS ~14 months vs high-dose octreotide in 1L G2–G3 GEP-NETs -
New trial · Aug 27, 2026 · NCT07743138
Phase 2 ivonescimab PD-1×VEGF bispecific antibody in previously treated ACC/PPGL -
Trial result · Aug 6, 2026 · NCT03049189
[177Lu]Lu-edotreotide (SSTR2-targeted PRRT) beats everolimus on PFS in progressive GEP-NETs (COMPETE) -
New trial · Jul 16, 2026 · NCT07661420
Phase 1 211At‑MABG targeted alpha radiotherapy (NET/norepinephrine transporter–avid) in advanced NETs